emapalumab-lzsg (gamifant) Report issue

Biologics mAb Orphan Drug FDA Approved FDA
AACT Drugs@FDA

Active Ingredient History

NOW
  • Now
Emapalumab, sold under the brand name Gamifant, is an anti-interferon-gamma (IFNγ) antibody medication used for the treatment of hemophagocytic lymphohistiocytosis (HLH), which has no cure.   Wikipedia

Chemistry

More Chemistry

Pharmacology

  • Mechanisms of Action:
  • Multi-specific: No
  • Black Box: Missing data
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: Missing data

Drug Pricing (per unit)

United States

$5187.4600 - $16630.5000
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

emapalumab-lzsg | ni-0501

Organizations (20)

Research & Development (20)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (13)

Approved Indications (1)


 

Lymphohistiocytosis, Hemophagocytic (approved 2018)

Experimental Indications - Clinical Trial Phases 1-4 (13)


 

Allografts (Phase 2)

Arthritis, Juvenile (Phase 3)

Autoimmune Diseases (Phase 2)

Granulomatous Disease, Chronic (Phase 1/Phase 2)

Healthy Volunteers (Phase 1)

Immune System Diseases (Phase 2)

Lupus Erythematosus, Systemic (Phase 3)

Lymphohistiocytosis, Hemophagocytic (Phase 4)

Macrophage Activation Syndrome (Phase 3)

Rare Diseases (Phase 1)

Recurrence (Phase 3)

SARS-CoV-2 (Phase 2/Phase 3)

Still's Disease, Adult-Onset (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 14
  • # of Trial Organizations: 20

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue